It’s unfortunately the one question that’s top of everyone’s minds – “When will there be a vaccine for Covid-19?” It’s a question that’s been asked since the pandemic broke out in January around the world and grew in scale in India around March.
One company on whom a lot of hopes have been pinned – not just in India, but also globally – is the Serum Institute based in Pune. As a matter of fact, much of the research and medical response to India’s Covid-19 needs is coming from Pune.
#Pune is one of the key epicenter of India’s battle against #COVID19, with organizations like:— Amit Paranjape (@aparanjape) July 21, 2020
National Institute of Virology@SerumInstIndia
Research & Innovation Cluster (NCL, IISER, SPPU, NCBS, Venture Center and more).
Startups (e.g. MyLab)@MCCIA_Pune @punetech
What’s most heartening, though, is the latest news about the Oxford Covid vaccine that’s expected to be available by end of the year, if Stage 3 trials go well. That the Serum Institute will exclusively produce this will let Indians feel far more comfortable about its availability. In a recent interview, Adar Poonawalla said, “We have said that we want to give half of our (vaccine) production to India and the other half to other countries on a pro-rata basis every month. The government has been supportive. We need to understand that this is a global crisis and people across the world need to be protected. It’s important that we equally immunise the entire world.”
See full interview here:
And yes, there is capacity to manufacture enough.
Our capacity right now till we build a new facility is going to be about 700 to 800 million dozes annually. So if we look at the four months that we got here we could make around 300 millions by December.Via News18.com